Abstract
Get full access to this article
View all access options for this article.
References
1.Mayo Collaborative Services v. Prometheus Laboratories , 132 S. Ct. 1289 (2012 ).
2.Association for Molecular Pathology v. Myriad Genetics, Inc. , 133 S. Ct 2107 (2013 ).
3.Alice Corp. v. CLS Bank International , 134 S. Ct. 2347 (2014 ). Patent claims reciting a computer-implemented, electronic escrow service for facilitating financial transactions covering abstract ideas are ineligible for patent protection .
4.
Entine
J.
FDA Balances costs, patient safety in the biologics and personalized medicine revolution . www.forbes.com/sites/jonentine/2012/07/23/fda-balances-costs-patient-safety-in-the-biologics-and-personalized-medicine-revolution-will-it-get-it-right-or-damage-the-miracle-industry/#4e8cf7951dd7
5.
Wu
H.
Balancing a biologics pipeline portfolio . Spring 11 . www.ddw-online.com/drug-discovery/p142736-balancing-a-biologics-pipeline-portfolio-spring-11.html
6.Article I, Section 8, Clause 8 of U.S. Constitution .
7.Diamond v. Chakrabarty , 447 U.S. 303 (1980 ).
8.
Chao
B
,
Maples
A.
An early look at Mayo's impact on personalized medicine . Patently-O Patent Law J , 2016 ; 10 . http://patentlyo.com/lawjournal/2016/04/personalized-medicine-patenting.html
9.U.S. Patent and Trademark Office . 2014 Interim Guidance on Subject Matter Eligibility, issued May 4, 2016 .
10.Article III, Section 2 of U.S. Constitution .
11.Public Law No. 114-153, signed by President 05/11/2016 .
13.
14.Economic Espionage Act of 1996; 18 U.S. Code §1831 .